On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades.The<a class="excerpt-read-more" href=" More ...
Plus, NBC News spoke to trans service members about their thoughts on President Trump's executive order banning trans people from enlisting and serving in the military.
Baird lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $320 from $325 and keeps an Underperform rating on the shares. The ...
Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares closed ...